Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Monday, 9 December 2019, 08:36 HKT/SGT

Source: Eisai
Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer's Disease Using Blood
- Presenting the Most Recent Data at the 12th Clinical Trials on Alzheimer's Disease (CTAD) Conference -

TOKYO, Dec 9, 2019 - (JCN Newswire) - Sysmex Corporation and Eisai Co., Ltd. are pursuing a joint project to develop a method of diagnosing Alzheimer's disease (AD) using blood, presented two posters showing the most recent data from the project. The presentations took place at the 12th Clinical Trials on Alzheimer's Disease (CTAD) conference, from December 4 to 7, 2019, in San Diego, California. At CTAD, Sysmex demonstrated on behalf of the two companies the possibility of understanding amyloid pathology in the brain from the brain-derived amyloid beta (Abeta) in plasma measured using its protein measurement platform, the HISCLTM series of fully automated immunoassay analyzers.

The total number of those living with dementia across the world is projected to reach 82 million in 2030 and 152 million in 2050, with the total global societal cost of dementia stemming from direct medical and social care costs and lower productivity being estimated to reach 220 trillion yen in 2030.(1) In Japan, the number of those with dementia is thought to have reached approximately 4.62 million in 2012 and is projected to grow to 7.30 million in 20252, with the total societal cost of this disease being estimated to be equivalent to 4.1%(3) of the gross domestic product (GDP) in 2025 (25.8 trillion yen(4)). Of these sufferers, those living with AD is thought to account for more than 60% of those living with dementia.(2)

It is conceivable that AD is a disease that results in synaptic dysfunction and neuronal cell death due to the tau deposition in neurons triggered by Abeta aggregation on the outside of neurons.

These brain changes cause the cognitive impairment and psychological and behavioral symptoms, suggesting that the Aβ aggregation and accumulation inside the brain are caused by AD before the presence of cognitive impairment appears, thus, it is believed that early diagnosis and early intervention is more effective in therapies targeting Abeta. Currently, amyloid PET and the plasma Abeta1-42/ Abeta1-40 ratio in cerebrospinal fluid (CSF) are used for detecting amyloid aggregates in the brain, but this puts significant burden on patients in terms of access, costs, and their physical wellbeing.(5)

In February 2016, Sysmex and Eisai signed a comprehensive non-exclusive agreement aimed at the development of new diagnostic tests in the field of dementia. By leveraging each other's technologies and knowledge, the objective has been to discover next-generation diagnostic reagents that will enable early diagnosis of dementia, selection of the most appropriate treatment options, and regular monitoring of the effects of such treatments.

At the Alzheimer's Association International Conference (AAIC) held in July 2019, Sysmex and Eisai presented their joint research on the correlation (Spearman's rank correlation coefficient (rs)6=0.502, p<0.001) between the Abeta1-42/ Abeta1-40 ratio in CSF and the Abeta1-42/ Aβ1-40 ratio in plasma, and demonstrated that it may be possible to understand amyloid pathology in the brain by measuring the plasma Abeta1-42/ Abeta1-40 ratio. Subsequently, the two companies have examined the correlation between the plasma Abeta1-42/ Abeta1-40 ratio and amyloid PET.

Sysmex and Eisai are engaged in joint development aimed at creating a simple method of
diagnosing AD from a blood sample. At CTAD, Sysmex demonstrated that it may be possible to understand pathological processes in the brain by measuring the plasma Abeta1-42/Abeta1-40 ratio based on the analysis result of the plasma Abeta1-42/Abeta1-40 ratio measured with the HISCL series as a predictive factor for Abeta PET positivity. Also it was presented a technique for verifying that the HISCL measuring system correctly captures Abeta in plasma on that occasion.

Sysmex and Eisai are working to create new diagnostic technologies for the prevention and treatment of dementia. Accordingly, the overarching aim is to contribute to the advancement of healthcare and improve the quality of life for those living with the disease and their families.

(1) World Alzheimer Report 2018
(2) Promotion of Comprehensive Measures against Dementia, Ministry of Health, Labour and Welfare
(3) Study on Economic Impact of Dementia in Japan, 2014 Health Labour Sciences Research Grant Annual Report
(4) Estimated by Sysmex based on Japan?s Medium-term Economic Outlook (February 2018), Daiwa Institute of Research
(5) Abeta, a peptide consisting of amino acid residues, is generated by excision from the
6 amyloid precursor protein. Abeta1-40 consists of 40 residues, is the dominant substance, and does not fluctuate significantly as AD progresses. In contrast, Abeta1-42, which consists of 42 residues, has high aggregability and a reduction in Abeta1-42 is detected from the early stage of AD. There are individual differences in the absolute value of Abeta as well as intra-individual variabilities, therefore, it has been reported that there is a high correlation between the Abeta1-42/Abeta1-40 ratio in CSF and amyloid PET.
(6) The correlation coefficient indicates the strength of the relationship between the two sets of pf data from the two quantitative data distributions. In this analysis, Spearman's rank correlation coefficient (rs), which is an index of correlation obtained from rank data, is calculated.

About Eisai

Eisai Co., Ltd. defines our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care (hhc) philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to address unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology. As a global pharmaceutical company, our mission extends to patients around the world through working with key stakeholders to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit

Johji Hayashi, Akinobu Seko
IR & Corporate Communication
Sysmex Corporation
1-5-1 Wakinohama-Kaigandori, Chuo-ku, Kobe 651-0073
Tel: 078-265-0508

Public Relations Department 
Eisai Co., Ltd.
Tel: 03-3817-5120

Dec 9, 2019 08:36 HKT/SGT
Source: Eisai

Eisai (TSE: 4523)

Topic: Press release summary
Sectors: BioTech
From the Asia Corporate News Network

Copyright © 2020 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

Sept 18, 2020 10:29 HKT/SGT
Eisai Presents Latest Data of Phase I Clinical Trial on Liposomal Formulation of Anti-Cancer Agent Halaven (Eribulin) at ESMO Virtual Congress 2020
Sept 17, 2020 08:59 HKT/SGT
Eisai Establishes Pharma Sales Subsidiary in Vietnam
Sept 11, 2020 09:41 HKT/SGT
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO Virtual Congress 2020
Sept 7, 2020 08:02 HKT/SGT
Eisai to Take over Manufacturing and Marketing Approval for Equfina 50mg Tablets (Safinamide Mesilate) in Japan from Meiji Seika Pharma
Aug 25, 2020 11:55 HKT/SGT
Eisai to Launch Sahne Medical Spray and Sahne Medical Cream
Aug 25, 2020 09:30 HKT/SGT
Eisai to Present Latest Data of Lemborexant at 34th Annual Sleep Meeting (SLEEP2020)
July 31, 2020 08:31 HKT/SGT
Eisai: Application for Additional Indication of Anti Cancer Agent Lenvima for Unresectable Thymic Carcinoma Submitted in Japan
July 22, 2020 16:04 HKT/SGT
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the Alzheimer's Association International Conference (AAIC) 2020
July 20, 2020 11:36 HKT/SGT
Eisai: Smartphone App for Vital Signs Measurement of Patients With the Novel Coronavirus Infection Experimental Study Project Adopted as AMED Project
July 14, 2020 08:20 HKT/SGT
Eisai: Initiation of New Phase III Clinical Study (Ahead 3-45) of ban2401 Preclinical (Asymptomatic) Alzheimer's Disease
More news >>
 News Alerts
Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6859 8575

Connect With us: